Abstract: The present disclosure relates generally to compositions and methods for treating fibroid in a patient in need thereof, which entails administering to the patient an effective amount of an agent that inhibits the expression or activity of TDO2 or IDO1.

Abstract: Cell populations, compositions, and methods are provided relating to target priming of macrophage cells. The macrophages, once primed or activated with a microorganism, can be used to prevent or treat infection by the microorganism. Likewise, once primed or activated by a tumor cell or tumor antigen, the macrophage cell can be used to prevent or treat tumor of the same kind. The priming can be carried out in vitro or ex vivo. The macrophages can be isolated from the subject of disease prevention or treatment.

Abstract: Computational systems and methods are described for identifying new type-II bacteriocins using a systemic consensus formula and other related criteria. Newly identified type-II bacteriocin peptides are tested experimentally and show potent microbiocidal activities.

Abstract: Computational systems and methods are described for identifying new ?-helical antimicrobial peptides using a systemic consensus formula. Newly identified ?-helical antimicrobial peptides are tested experimentally and show potent microbiocidal activities.

Abstract: The present disclosure relates generally to compositions and methods for treating, preventing, or slowing the rate of development of a disease or condition mediated by a nonsense mutation in the bone morphogenetic protein receptor type II (Bmpr2) in a subject in need thereof. The method entails administering to the subject a compound of the present disclosure, such as GJ103 and a salt thereof.

Abstract: Methods of modulating the interaction between ?-amyloid and ?7-nAChR are provided. Aspects of the methods include administering to the subject an effective amount of a naphthalene derivative active agent. Compositions and kits for practicing the subject methods are also provided. The methods, compositions and kits find use in treating a variety of applications, such as treating a subject for a neurodegenerative disease, e.g., Alzheimer's disease.

Abstract: Disclosed herein are methods and compositions useful for preventing or reducing corneal haze of opacification resulting from Limbal Stem Cell Deficiency (LSCD). The invention comprises a method of preventing or treating corneal opacification, comprising administering to a subject a sufficient amount of a proteasome modulator. The invention also comprises a method of preventing or treating corneal opacification, comprising administering to a subject a sufficient amount of a proteasome modulator. In addition, the invention comprises a method of administering to a subject suffering from corneal opacification with a sufficient amount of proteasome modulator, resulting in reduction of Keratin proteins in the cornea of the subject.

Abstract: Peptides suitable for preparation of lung surfactants are described. Examples include one that include a first fragment comprising the amino acid sequence of XWLXRALIKRIQAZI (SEQ ID NO: 1) or a first amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 and a second fragment comprising the amino acid sequence of RZLPQLVXRLVLRXS (SEQ ID NO: 2) or a second amino acid sequence having at least 90% sequence identity to SEQ ID NO: 2, wherein X is any amino acid but at least one amino acid at the X positions is not cysteine, or Z is any amino acid but at least one amino acid at the Z positions is not methionine. Surfactants that contain such peptides, and related compositions, methods of preparing and using the compositions are also described.